Abstract Body

Background

Mozambique has a high HIV incidence, with adolescent girls and young women (AGYW) accounting for 27% of the estimated 91,644 annual infections in 2024. Oral pre-exposure prophylaxis (PrEP) has been implemented in Nampula Province since 2019. In 2024, 13,585 AGYW in Nampula initiated oral PrEP, however, challenges persist, with only 23% remaining on PrEP one year after initiation. To improve continuity on PrEP, long-acting cabotegravir (Cab-LA), taken bimonthly (as opposed to daily oral PrEP), was introduced in 2024.

Methods

Under a pilot program, Cab-LA was offered to AGYW (aged 15–24 years) at one health center in Nampula City. Following the national testing algorithm, Cab-LA clients were screened for signs and symptoms of acute HIV infection (AHI) and tested using rapid HIV diagnostic tests. Those testing negative had a blood sample taken before receiving Cab-LA, which was tested via polymerase chain reaction (PCR). PCR results were available at the second visit, and were used to determine continuation on Cab-LA. We analyzed data from routine aggregated clinic reports.

Results

 From December 2024 to August 2025, 902 AGYW were offered Cab-LA and 490 (54%) AGYW initiated Cab-LA (339 [69%] aged 15-19 years and 151 [31%] aged 20-24 years). Among them, 21 (4%) were pregnant and six (1%) were breastfeeding. Of the 412 AGYW who did not initiate Cab-LA, 121 (29%) preferred oral PrEP, 121 (29%) feared injections, and 113 (27%) feared using a new product. The return rate for the second injection was 59% (287/490). No participant with an initial HIV negative PCR test seroconverted by the subsequent testing, made 6 months after initiation. Ten (2%) participants tested HIV positive on PCR from the first visit and stopped Cab-LA at the second visit. Among those, five were aged 15–19 years, one reported transactional sex work, and two had symptoms of AHI. As of August 31, among the seven participants linked to HIV treatment, one out of five with CD4 tests had a CD4 <200 cells/mL. The three participants not linked to treatment could not be contacted.

Conclusions

Data on Cab-LA acceptability and effectiveness among AGYW in Mozambique will be used to inform future scale-up long-acting PrEP options. Additionally, providing PCR HIV testing at the start of Cab-LA can help identify individuals who are HIV-positive and need to discontinue injections to begin antiretroviral therapy.